Format: QMS/FMT/002 Revision No: 1 Effective Date: 20 June		Department/Division/Office/Unit	FDISM/PVSM		
Document Type: Form		Doc. No	: FDISM/PVSM /FOM/016		
	Title:		Revision Number	: 2	
	SUSPECTED POOR QUALITYPRODUCT REPORTING FORM		Revision Date:	: 05/08/2022	
			Effective Date	: 12/08/2022	
RWANDA FDA			Review Due Date	: 05/08/2025	
Rwanda Food and Drugs Authority			Ref Doc.	:FDISM/PVSM/GDL/003	

I. PRODUCT CATEGORY (Tick as appropriate)												
Medicinal product Vaccine Other Biological Products Herbal product Other (Please Specify):												
II. PRODUCT DETAILS												
Brand name						Generic Name						
Batch/Lot Nº		Manufacturin g Date			Expiry date			Date of receipt				
Name of ma	anufacturer	g Date			Physical A	ddress and		leccipt				
Name of Di	vistributor/Supplier					Country of Origin Distributor/ Supplier's						
					Address							
	UCT FORMULAT	ION			IV. DESCRIPTION OF PRODUCT COMPLAINT							
Tablets /capsules Suspension/Syrup Injectable/Infusions Creams/Ointment/Liniment/Paste Pessaries Suppository Powder for reconstitution of oral suspension Powder for reconstitution of injection Ear/Eye drops Diluents Nebulizing solutions Other (Please Specify)				Color/odor change Molding Turbidity Mislabelling Poor Packaging/ lack of patient leaflet/ lack measuring devices Therapeutic ineffectiveness Particulate matter Seal Integrity of packs and/ or Leakage Caking Separating Incomplete packs Powdering/crumbling Suspected falsified/ Substandard Others <i>Specify</i>)								
							••					
V. PRODU	ICT STORAGE CO	ONDITIONS										
V. PRODUCT STORAGE CONDITIONS Does product require refrigeration? YES_NO_ Does product require protection from light? YES_NO_ Does product require protection from Moisture? YES_NO_ Was it stored following manufacturer/Rwanda FDA guidelines?YES_NO_						Other Storage details (if necessary):				(if necessary):		
VI. CIRCU	JMSTANCE AND	FIME OF THE F	POOR-	QUALITY DET	ECTION		VII. A	CTION TAI	KEN			
When did you notice the poor-quality problem? Before taking/administering the product While taking/administering the product After taking/administering the product After taking/administering the product When the patient returned the product Other(specify).			er Visual inspection er quality control	on		 Stop Taking/Administration of the product Quarantining the product Returning the product to the supplier Other (specify): 						
Have you e	xperienced any adve	rse event after tak	ing this	medicine? YES	NO	f YES , plea	se comp	lete the ADR	/AEFI Rep	porting Form.		
VIII. REPO	ORTER INFORMA	ATION										
Name of rep				Qualification:			Phone	number:				
Name of He Facility	ne of Health District:		District:		Report Reference No:							
E-mail Add	ress:	Contact/Tel No:					Date of report:					
All information is held in strict confidentiality and will not disclose reporter's identity in response to any public request. Information supplied will contribute to the improvement of safety and visilance of Medical Products in Rwanda. Once this form is completed please send it to Rwanda FDA												

contribute to the improvement of safety and vigilance via the following email: <u>pv sm@rwandafda.gov.rw</u>